Visit our new Alternative Investment section.Click here

Less Ads, More Data, More Tools Register for FREE

Alphawave says key regulatory approvals received for Qualcomm takeover

Tue, 25th Nov 2025 16:09

(Alliance News) - Alphawave IP Group PLC on Tuesday said several regulatory conditions for its recommended takeover by Qualcomm Inc have now been satisfied, allowing the transaction to progress to the court-sanction stage.

The London-based semiconductor designer said the US Hart-Scott-Rodino waiting period expired on October 22, while Germany's Federal Cartel Office confirmed on Monday that its prohibition criteria were not met.

The Canadian Competition Act waiting period also expired on November 14.

Alphawave said the only remaining regulatory approval relates to merger control clearance in South Korea. The company expects this to be satisfied or waived before the court hearing to sanction the scheme, scheduled for December 16.

Subject to that approval, the scheme is expected to become effective on December 18. Election deadlines for alternative consideration options fall on December 9 and December 15.

Further updates will be announced via a regulatory information service, Alphawave added.

By Eva Castanedo, Alliance News reporter

Comments and questions to newsroom@alliancenews.com

Copyright 2025 Alliance News Ltd. All Rights Reserved.


Shares in this article

Related News

IN BRIEF: Qualcomm completes USD2.4 billion purchase of Alphawave IP
18 Dec 2025

IN BRIEF: Qualcomm completes USD2.4 billion purchase of Alphawave IP

Qualcomm Inc - San Diego, California-based communications technology company - Completes acquisition of Leeds, England-based high-speed connectivity s...

Alphawave IP interim loss widens ahead of takeover by Qualcomm
29 Sep 2025

Alphawave IP interim loss widens ahead of takeover by Qualcomm

(Alliance News) - Alphawave IP Group PLC on Monday reported higher revenue but a wider loss during the first half of the year, as it prepares for its ...

LONDON BRIEFING: AstraZeneca plans listing changes; GSK names next CEO
29 Sep 2025

LONDON BRIEFING: AstraZeneca plans listing changes; GSK names next CEO

(Alliance News) - AstraZeneca plans changes to its US listing and to retain its position in London, GSK promotes its chief commercial officer to lead ...

Astrazeneca + 6 more shares